Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Reichardt et al.|The Lancet|2012Cited by 1.4k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal TumorsGeorge D. Demetri, Jeffrey D. Wayne, Margaret von Mehren et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 1.2k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, Sant P. Chawla et al.|The Lancet|2016Cited by 766
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyJordi Barretina, Samuel Singer, Shantanu Banerji et al.|Nature Genetics|2010Cited by 725
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice GuidelinesGeorge D. Demetri, John Zalcberg, Robert S. Benjamin et al.|Journal of the National Comprehensive Cancer Network|2007Cited by 636